Shopping Cart

Expired activity

Please go to the PowerPak homepage and select a course.

Faculty

Nathan Steinle, MD (Moderator)
California Retina Consultants
Santa Barbara, CA

David Eichenbaum, MD, FAAO
Collaborative Associate Professor
Department of Ophthalmology
University of South Florida Morsani
College of Medicine
Director of Research, Retina Vitreous Associates of Florida
Tampa, FL

Sean Goodale, CPA, MBA
Chief Executive Officer
Retina Associates
Kansas City, MO

Alison L. Ratliff, MBA
Chief Executive Officer
South Coast Retina Center
Santa Barbara, CA

Ankoor R. Shah, MD
Retina Consultants of Houston
Houston, TX

Program Overview

Anti-VEGF therapy has revolutionized retinal care and turned many unavoidable blinding diseases into pathologies that can be controlled by restoring and preserving vision. Yet as the use of anti-VEGF medications continues to grow, so do the challenges of access to these medications. The following content showcases the challenges faced by physicians, practice administrators, and payors in the journey to providing quality care of patients with retinal disease.

Target Audience

This certified CME activity is designed for retina specialists, ophthalmologists, pharmacists, and other professionals involved in the treatment and management of patients with retinal disorders.

RELEASE DATE

OCTOBER 1, 2020

EXPIRATION DATE

OCTOBER 1, 2021

Learning Objectives

Upon completion of this activity, the participant should be able to:

• Implement the most up-to-date decision-making tools to determine optimal treatment for each patient and improve communication with patients about their treatment options.
• Advocate against prior authorizations and step policies and learn how to appeal them.
• Understand and analyze the potential impact of the Drug Quality and Security Act and identify opportunities to campaign for continued access to compounded ophthalmologic drugs.
• Recognize how MACRA affects ophthalmology practices and its potential impact on how retina specialists treat their patients with anti-VEGF agents.

ACCREDITATION STATEMENT

The University of South Carolina College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. These application-based activities are each accredited for 1 home study contact hour (0.1 CEU) for pharmacists. ACPE UAN 0062-9999-20-201-H01-P.

How to Earn Credit

Participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the posttest and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 75% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 75%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.

DISCLOSURE POLICY

It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Nathan Steinle, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alimera Sciences , Apellis, Carl Zeiss Meditec, Genentech, Novartis, Opthea, Regeneron Pharmaceuticals, Regenxbio,  and Vortex Surgical. Grant Research Support: Genentech, Novartis and Regeneron Pharmaceuticals. Speaker’s Bureau: Alimera, Genentech, Notal Vision, Novartis, and Regeneron Pharmaceuticals. Stock/Shareholder: Regeneron Pharmaceuticals and Vortex Surgical.

David Eichenbaum, MD, FAAO, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alimera Sciences, Allergan, DORC, Eyepoint Pharmaceuticals, Genentech, Gyroscope, Kodiak, Novartis, Recens Medical, and Regeneron Pharmaceuticals. Grant/Research Support: Alimera, Allergan, Chengdu, Clearside Biomedical, Genentech, Gyroscope, Kodiak, Mylan, NGM, Novartis, Opthea, and Ophthotech. Speaker’s Bureau: Allergan, Genentech, and Novartis. Stock/Shareholder: Boston Image Reading Center, Clearside Biomedical, Hemera Biosciences, and Network Eye.

Sean Goodale, CPA, MBA, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Speaker’s Bureau: Genentech and Regeneron Pharmaceuticals.

Alison L. Ratliff, MBA, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Novartis, and Regenxbio. Speaker’s Bureau: Genentech and Regeneron Pharmaceuticals.

Ankoor R. Shah, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Novartis and Ocular Therapeutix.

The staff and planners involved in this activity have no financial relationships with commercial interests. Caitlin Mardis, PharmD, University of South Carolina College of Pharmacy staff, has no financial relationships with commercial interests.

OFF-LABEL STATEMENT

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The University of South Carolina College of Pharmacy, or Regeneron Pharmaceuticals.